RxDoctor Payments Data

Arun Sendilnathan, MD

Hematology & Oncology · Hamilton, OHNPI 1013298223

Payments from drug & device makers

$8,881in general payments, 2019–2025

Across 45 payments — averaging $197.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$5K
  • G1 Therapeutics, Inc.$2K
  • Adaptive Biotechnologies Corporation$1K
  • Tempus AI, Inc$274
  • E.r. Squibb & Sons, L.L.C.$252
  • AbbVie$217
  • plus $658 from 7 others

What the payments were for

  • Consulting fees$1,10012%
  • Speaking & faculty fees$4,00045%
  • Travel & lodging$1,77120%
  • Food & beverage$1,96522%
  • Education$451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,881 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$81,205
Medicare patients
182
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide39$467,702
IbrancePalbociclib22$342,336
EliquisApixaban51$43,096
XareltoRivaroxaban15$14,052
CreonLipase/Protease/Amylase21$2,983
Anastrozole113$2,231
Ondansetron Hcl41$1,605
Potassium Chloride69$1,559
Olanzapine77$1,091
Prochlorperazine Maleate72$698
Mirtazapine61$652
Doxycycline Hyclate18$641
Morphine Sulfate ErMorphine Sulfate33$617
Exemestane13$614
Lidocaine-PrilocaineLidocaine/Prilocaine38$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$121$467,70239 claims
Johnson & JohnsonXarelto$125$14,05215 claims
AbbVieCreon$217$2,98321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →